Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators

Forns, Joan; Pottegård, Anton; Reinders, Tammo; Poblador‐Plou, Beatriz; Morros, Rosa; Brandt, Lena; Cainzos‐Achirica, Miguel; Hellfritzsch, Maja; Schink, Tania; Prados‐Torres, Alexandra; Giner-Soriano, Maria; Hägg, David; Hallas, Jesper; Martínez, Jordi; Jacquot, Emmanuelle; Deltour, Nicolas; Perez‐Gutthann, Susana; Pladevall, Manel; Reutfors, Johan

doi:10.1016/j.jad.2019.02.010

Cited by 51 publications

(40 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S7). Its comparable low efficacy may be a reason why agomelatine is still one of the less frequently used antidepressants [47]. The present analysis suggests potential dose escalation until 40 mg/day FE , which is the upper limit of its licensed range (Table 2).…”

Section: Discussionmentioning

confidence: 79%

“…Escitalopram, after citalopram one of the most commonly used antidepressants [47], has a unique mechanism among SSRIs. While the exact mechanism is unclear, the most common explanation why escitalopram seems to be more effective than citalopram, is that there is a synaptic interaction for the racemat citalopram (which consists of the S-and R-citalopram enantiomers), in that the presence of R-citalopram somehow inhibits the more active S-citalopram in the binding to the serotonin (5-hydroxytryptamine [5-HT]) site of the serotonin transporter (SERT) [48,49].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis

Holper

2020

eClinicalMedicine

View full text Add to dashboard Cite

A B S T R A C TBackground: The meta-analysis by Furukawa et al. (The Lancet Psychiatry 2019, 6(7)) reported optimal doses for antidepressants in adult major depressive disorder (MDD). The present reanalysis aimed to adjust optimal doses in dependence on age. Methods: Analysis was based on the same dataset by Cipriani et al. (The Lancet 2018, 391(10128)) comparing 21 antidepressants in MDD. Random-effects Bayesian network meta-analysis was implemented to estimate the combined covariate action using restricted cubic splines (RCS). Balanced treatment recommendations were derived for the outcomes efficacy (response), acceptability (dropouts for any reason), and tolerability (dropouts due to adverse events). Findings: The combined covariate action of dose and age suggested agomelatine and escitalopram as the best-balanced antidepressants in terms of efficacy and tolerability that may be escalated until 40 and 60 mg/day fluoxetine equivalents (mg/day FE ), respectively, for ages 30À65 years. Desvenlafaxine, duloxetine, fluoxetine, milnacipran, and vortioxetine may be escalated until 20À40 mg/day FE , whereas bupropion, citalopram, mirtazapine, paroxetine, and venlafaxine may not be given in doses > 20 mg/day FE . Amitriptyline, clomipramine, fluvoxamine, levomilnacipran, reboxetine, sertraline, and trazodone revealed no relevant balanced benefits and may therefore not be recommended for antidepressant treatment. None of the antidepressants was observed to provide balanced benefits in patients >70 years because of adverse events exceeding efficacy. Interpretation: Findings suggest that the combined covariate action of dose and age provides a better basis for judging antidepressant clinical benefits than considering dose or age separately, and may thus inform decision makers to accurately guide antidepressant dosing recommendations in MDD. Funding: No funding.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis

Holper

2020

eClinicalMedicine

View full text Add to dashboard Cite

show abstract

“…Moreover, the study was not hampered by lack of power in the analyses of DP due to various diagnostic groups which is often the case even in population-based samples 21. The frequency of antidepressants use in our sample was similar as in the general Swedish population 22 23. However, we also need to address some limitations.…”

Section: Discussionmentioning

confidence: 89%

Changes in prescription of antidepressants and disability pension due to back pain, compared with other musculoskeletal and other somatic diagnoses: a cohort study in Sweden

et al. 2019

View full text Add to dashboard Cite

ObjectivesThe aim was to investigate differences in the prescription of antidepressants during the transition to disability pension (DP) comparing DP due to back pain with DP due to other musculoskeletal and DP due to other somatic diagnoses.DesignA population-based cohort study with follow-up 3 years before and after the event. Estimated prevalence and adjusted ORs with 95% CIs for antidepressant prescription were computed for the 7-year window (ie, t-3 to t+3) around the DP by generalised estimating equations for repeated measures.Setting and participantsThis Swedish population-based nationwide study with registry data included individuals aged 18–64 years, with DP due to back pain (n=2011), DP due to other musculoskeletal (n=3548) or DP due to other somatic diagnoses (n=11 809).Primary outcome measuresPrescription of antidepressants.ResultsBefore DP, the prevalence of prescription of antidepressants was stable in DP due to back pain, but increased for the other DP groups. Similarly, the likelihood of prescription increased only marginally before DP due to back pain (ORs from 0.86 at t-3 to 1.10 at t-1), but clearly in DP due to musculoskeletal (from 0.42 to 1.15) and somatic diagnoses (from 0.29 to 0.98). Both prevalence measures and risks remained at the elevated levels after DP.ConclusionsPathways to DP due to musculoskeletal and somatic diagnoses seem to be partly driven by adverse mental health, which remains at a higher level after DP. The increasing prescription of antidepressants prior to DP suggests that special attention should be paid to mental health for prevention of DP. The period after DP needs attention to avoid deterioration of mental health.

show abstract

“…Cipriani et al showed that mirtazapine, venlafaxine, among 5 other antidepressants, had a better efficacy; citalopram among a few others was more acceptable, while duloxetine and venlafaxine with 5 others had the lowest acceptability [20]. Also Frons et al demonstrated that between 2009-2014, citalopram followed by mirtazapine was the most used antidepressant, while paroxetine and agomelatine were the least prescribed antidepressants [21]. In Germany, 44.1 % of adults are of normal weight, with the prevalence of overweight increasing with age [22].…”

Section: Discussionmentioning

confidence: 99%

Drug-Induced Liver Injury (DILI) in Patients with Depression Treated with Antidepressants: A Retrospective Multicenter Study

Ueberberg

Frommberger

Messer³

et al. 2020

Pharmacopsychiatry

View full text Add to dashboard Cite

Introduction Drug-induced liver injury (DILI) is the 4th most common cause of liver damage in Western countries and can be caused by antidepressants. Methods Against the background of increasing antidepressant prescriptions and increasing use of polypharmacy, we analyzed administered antidepressants and other pharmacological substances, liver toxicity, comorbid somatic secondary diseases together with the occurrence of DILI in a patient population of 6 centers throughout Germany. Results The majority of the enrolled 329 patients received polypharmacological treatment in an inpatient setting. During antidepressant treatment 5.1% of the patients had elevated serum transaminase levels, whereby exactly and not more than 1 criterion proposed to be indicative for DILI, was fulfilled by 3 patients (0.9%). Discussion During patient characterization it becomes clear that a sensitization for relevant risk constellations causing liver injury in MDD patients is relevant to prevent further serious adverse events.

show abstract

Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators

Cited by 51 publications

References 23 publications

Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis

Optimal doses of antidepressants in dependence on age: Combined covariate actions in Bayesian network meta-analysis

Changes in prescription of antidepressants and disability pension due to back pain, compared with other musculoskeletal and other somatic diagnoses: a cohort study in Sweden

Drug-Induced Liver Injury (DILI) in Patients with Depression Treated with Antidepressants: A Retrospective Multicenter Study

Contact Info

Product

Resources

About